Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mats Ehinger

Showing results (51-60 of 75) with videos related to

Pageof 8
Sort By:
European Journal of Haematology|May 21, 2016
Patient-tailored analysis of minimal residual disease in acute myeloid leukemia using next-generation sequencingErik B R Malmberg, Sara Ståhlman, Anna Rehammar, et al.
Leukemia Research Reports|December 31, 2015
Young woman with mild bone marrow dysplasia, GATA2 and ASXL1 mutation treated with allogeneic hematopoietic stem cell transplantationAnna Lübking, Sebastian Vosberg, Nikola P Konstandin, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 7, 2015
Lentiviral gene therapy using cellular promoters cures type 1 Gaucher disease in miceMaria Dahl, Alexander Doyle, Karin Olsson, et al.
Blood|June 30, 2016
Lenalidomide-bendamustine-rituximab in patients older than 65 years with untreated mantle cell lymphomaAlexandra Albertsson-Lindblad, Arne Kolstad, Anna Laurell, et al.
British Journal of Haematology|April 2, 2014
SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma--a Nordic Lymphoma Group studyLena Nordström, Sandra Sernbo, Patrik Eden, et al.
International Journal of Laboratory Hematology|May 30, 2021
Comparison of RNA- and DNA-based methods for measurable residual disease analysis in NPM1-mutated acute myeloid leukemiaLouise Pettersson, Sofie Johansson Alm, Alvar Almstedt, et al.
Leukemia & Lymphoma|March 15, 2021
Is there an impact of measurable residual disease as assessed by multiparameter flow cytometry on survival of AML patients treated in clinical practice? A population-based studyAldana Rosso, Gunnar Juliusson, Fryderyk Lorenz, et al.
Cell Reports|May 28, 2020
CXCR4 Signaling Has a CXCL12-Independent Essential Role in Murine MLL-AF9-Driven Acute Myeloid LeukemiaRamprasad Ramakrishnan, Pablo Peña-Martínez, Puneet Agarwal, et al.
American Journal of Hematology|July 31, 2013
World Health Organization-defined classification of myeloproliferative neoplasms: morphological reproducibility and clinical correlations--the Danish experienceAnn Brinch Madelung, Henrik Bondo, Inger Stamp, et al.
Blood|March 15, 2003
Mutated VH genes and preferential VH3-21 use define new subsets of mantle cell lymphomaSarah H Walsh, Mia Thorsélius, Anna Johnson, et al.
Pageof 8

Showing results (51-60 of 75) with videos related to

Sort By:
Pageof 8
European Journal of Haematology|May 21, 2016
Patient-tailored analysis of minimal residual disease in acute myeloid leukemia using next-generation sequencingErik B R Malmberg, Sara Ståhlman, Anna Rehammar, et al.
Leukemia Research Reports|December 31, 2015
Young woman with mild bone marrow dysplasia, GATA2 and ASXL1 mutation treated with allogeneic hematopoietic stem cell transplantationAnna Lübking, Sebastian Vosberg, Nikola P Konstandin, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 7, 2015
Lentiviral gene therapy using cellular promoters cures type 1 Gaucher disease in miceMaria Dahl, Alexander Doyle, Karin Olsson, et al.
Blood|June 30, 2016
Lenalidomide-bendamustine-rituximab in patients older than 65 years with untreated mantle cell lymphomaAlexandra Albertsson-Lindblad, Arne Kolstad, Anna Laurell, et al.
British Journal of Haematology|April 2, 2014
SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma--a Nordic Lymphoma Group studyLena Nordström, Sandra Sernbo, Patrik Eden, et al.
International Journal of Laboratory Hematology|May 30, 2021
Comparison of RNA- and DNA-based methods for measurable residual disease analysis in NPM1-mutated acute myeloid leukemiaLouise Pettersson, Sofie Johansson Alm, Alvar Almstedt, et al.
Leukemia & Lymphoma|March 15, 2021
Is there an impact of measurable residual disease as assessed by multiparameter flow cytometry on survival of AML patients treated in clinical practice? A population-based studyAldana Rosso, Gunnar Juliusson, Fryderyk Lorenz, et al.
Cell Reports|May 28, 2020
CXCR4 Signaling Has a CXCL12-Independent Essential Role in Murine MLL-AF9-Driven Acute Myeloid LeukemiaRamprasad Ramakrishnan, Pablo Peña-Martínez, Puneet Agarwal, et al.
American Journal of Hematology|July 31, 2013
World Health Organization-defined classification of myeloproliferative neoplasms: morphological reproducibility and clinical correlations--the Danish experienceAnn Brinch Madelung, Henrik Bondo, Inger Stamp, et al.
Blood|March 15, 2003
Mutated VH genes and preferential VH3-21 use define new subsets of mantle cell lymphomaSarah H Walsh, Mia Thorsélius, Anna Johnson, et al.
Pageof 8